{"disease":{"id":"open-angle","name":"open angle"},"drugs":{"marketed":[{"drug_id":"nab-paclitaxel","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"paclitaxel","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"nabpaclitaxel","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"clonidine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Catapres-Tts-1","generic_name":"CLONIDINE","company_name":"Lavipharm","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"dorzolamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trusopt","generic_name":"DORZOLAMIDE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Carbonic Anhydrase Inhibitor","quality_score":51,"revenue":null,"mechanism":"Trusopt works by inhibiting the enzyme carbonic anhydrase 2, which is involved in the production of aqueous humor in the eye."},{"drug_id":"carbachol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Miostat","generic_name":"CARBACHOL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"carbachol","quality_score":48,"revenue":null,"mechanism":"Miostat works by mimicking the action of the neurotransmitter acetylcholine to increase the outflow of aqueous humor and reduce intraocular pressure."},{"drug_id":"levobunolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betagan","generic_name":"LEVOBUNOLOL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"brimonidine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alphagan","generic_name":"BRIMONIDINE","company_name":"Senju Pharmaceutical Co., Ltd","drug_phase":"marketed","molecular_target":"Alpha-2C adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"levobetaxolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betaxon","generic_name":"LEVOBETAXOLOL","company_name":"Alcon Pharms Ltd","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"levobetaxolol","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"aceclidine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aceclidin","generic_name":"ACECLIDINE","company_name":"","drug_phase":"marketed","molecular_target":"muscarinic receptors","drug_class":"aceclidine","quality_score":44,"revenue":null,"mechanism":"VIZZ, a pupil-selective miotic, contracts the iris sphincter muscle to improve vision by extending depth of focus."},{"drug_id":"apraclonidine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Iopidine","generic_name":"APRACLONIDINE","company_name":"Harrow Health","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"clonidin","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clonidin","company_name":"Medical University of Vienna","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"azopt","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Azopt","company_name":"Alcon Research","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"befunolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bentos","generic_name":"BEFUNOLOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"befunolol","quality_score":null,"revenue":null,"mechanism":"Bentos works by reducing the production of fluid in the eye, thereby lowering intraocular pressure."},{"drug_id":"physostigmine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cogmine","generic_name":"PHYSOSTIGMINE","company_name":"","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"physostigmine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"metipranolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Optipranolol","generic_name":"METIPRANOLOL","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"brinzolamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azopt","generic_name":"BRINZOLAMIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"carbonic anhydrase II","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Brinzolamide reduces intraocular pressure by inhibiting carbonic anhydrase II, decreasing aqueous humor secretion."},{"drug_id":"xalatan","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xalatan","company_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"epinephrine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epipen","generic_name":"epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epipen works by stimulating the alpha-1D adrenergic receptor to rapidly increase heart rate, blood pressure, and bronchodilation."},{"drug_id":"latanoprost","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xalatan","generic_name":"LATANOPROST","company_name":"Thea Pharma","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"Prostaglandin Analog [EPC]","quality_score":75,"revenue":null,"mechanism":"Xalatan works by increasing the outflow of fluid from the eye, reducing pressure."},{"drug_id":"travoprost","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Travatan","generic_name":"TRAVOPROST","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"Prostaglandin Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Travatan works by increasing the outflow of fluid from the eye to reduce pressure."},{"drug_id":"dichlorphenamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keveyis","generic_name":"DICHLORPHENAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Keveyis works by inhibiting the enzyme carbonic anhydrase, which is involved in the production of aqueous humor in the eye."},{"drug_id":"bimatoprost","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumigan","generic_name":"BIMATOPROST","company_name":"","drug_phase":"marketed","molecular_target":"Aldo-keto reductase family 1 member C3","drug_class":"Prostaglandin Analog [EPC]","quality_score":75,"revenue":null,"mechanism":"Lumigan works by increasing the outflow of fluid from the eye to reduce pressure."},{"drug_id":"methazolamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neptazane","generic_name":"METHAZOLAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 3","drug_class":"methazolamide","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"acetazolamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"lidocaine-hydrochloride-and-epinephrine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride And Epinephrine","generic_name":"Epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epinephrine works by stimulating the alpha-1D adrenergic receptor to increase heart rate and blood pressure, and to constrict blood vessels."},{"drug_id":"carteolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ocupress","generic_name":"CARTEOLOL","company_name":"","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"dipivefrine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dipivefrin","generic_name":"dipivefrine","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"Adrenergic Receptor Agonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pilocarpine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Salagen","generic_name":"PILOCARPINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Cholinergic Receptor Agonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"latanoprostene-bunod","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyzulta","generic_name":"LATANOPROSTENE BUNOD","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Vyzulta works by activating the Prostaglandin F2-alpha receptor, which increases the outflow of aqueous humor from the eye, thereby reducing intraocular pressure."},{"drug_id":"netarsudil","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhopressa","generic_name":"NETARSUDIL","company_name":"Alcon Labs Inc","drug_phase":"marketed","molecular_target":"rho kinase","drug_class":"Rho Kinase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Netarsudil reduces intraocular pressure by increasing aqueous humor outflow through the trabecular meshwork."},{"drug_id":"betaxolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betoptic","generic_name":"BETAXOLOL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":10,"revenue":null,"mechanism":"Betaxolol works by blocking the beta-1 adrenergic receptor in the heart and eyes, reducing heart rate and pressure, and decreasing intraocular pressure."},{"drug_id":"echothiophate","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phospholine Iodide","generic_name":"ECHOTHIOPHATE","company_name":"Fera Pharms Llc","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Cholinesterase Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"epinephrin","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epinephrin","company_name":"United States Naval Medical Center, San Diego","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"travatan","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Travatan","company_name":"Alcon Research","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abraxane","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"salagen","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Salagen","company_name":"Alberta Health services","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"acetazolamide","indication_name":"Chronic simple (open-angle) glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"taxol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dichlorophen","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Didroxan","generic_name":"DICHLOROPHEN","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1","drug_class":"dichlorophen","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"brimonidine-tartrate","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alphagan","generic_name":"BRIMONIDINE TARTRATE","company_name":"Senju Pharmaceutical Co., Ltd","drug_phase":"marketed","molecular_target":"Alpha-2C adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":41,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04381611","title":"INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"Dr. Kaweh Mansouri","has_results":false},{"nct_id":"NCT03695224","title":"Matching Glaucoma With Impaired Cognition","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01853085","title":"A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons","phase":"","overall_status":"COMPLETED","enrollment_count":1830,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT06434155","title":"Social History and Glaucoma Progression","phase":"","overall_status":"COMPLETED","enrollment_count":1584,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT01999348","title":"A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting","phase":"","overall_status":"COMPLETED","enrollment_count":1553,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04454190","title":"Development and Validation of a Model to Predict Fast Progression in Glaucoma","phase":"","overall_status":"TERMINATED","enrollment_count":1152,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05710198","title":"Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Omikron Italia S.r.l.","has_results":false},{"nct_id":"NCT02571712","title":"Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"Allergan","has_results":false},{"nct_id":"NCT05269680","title":"STAR-LIFE: a Post-market Registry on MINIject","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"iSTAR Medical","has_results":false},{"nct_id":"NCT01881425","title":"InnFocus MicroShunt Versus Trabeculectomy Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":732,"lead_sponsor_name":"InnFocus Inc.","has_results":true},{"nct_id":"NCT03395535","title":"Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":718,"lead_sponsor_name":"Moorfields Eye Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT02558400","title":"Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":718,"lead_sponsor_name":"Aerie Pharmaceuticals","has_results":true},{"nct_id":"NCT04630808","title":"MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":696,"lead_sponsor_name":"Nicox Ophthalmics, Inc.","has_results":false},{"nct_id":"NCT04445519","title":"Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":691,"lead_sponsor_name":"Nicox Ophthalmics, Inc.","has_results":true},{"nct_id":"NCT03450629","title":"Evaluation of Safety and Efficacy of PDP-716","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":682,"lead_sponsor_name":"Sun Pharma Advanced Research Company Limited","has_results":true},{"nct_id":"NCT03657797","title":"Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":656,"lead_sponsor_name":"Nicox Ophthalmics, Inc.","has_results":true},{"nct_id":"NCT01026831","title":"Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":643,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03896633","title":"Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":637,"lead_sponsor_name":"Bausch & Lomb Incorporated","has_results":true},{"nct_id":"NCT05022004","title":"A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":599,"lead_sponsor_name":"Sun Pharmaceutical Industries Limited","has_results":true},{"nct_id":"NCT02247804","title":"Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":594,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03519386","title":"Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Glaukos Corporation","has_results":true},{"nct_id":"NCT02914509","title":"Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":565,"lead_sponsor_name":"Ocular Therapeutix, Inc.","has_results":true},{"nct_id":"NCT03868124","title":"Clinical Study Comparing Two Models of a Travoprost Intraocular Implant","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":560,"lead_sponsor_name":"Glaukos Corporation","has_results":true},{"nct_id":"NCT02250651","title":"Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":528,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03850782","title":"Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04334564","title":"Effect of Ginkgo Biloba Capsule on Visual Function of Primary Open-angle Glaucoma With Blood Stasis Syndrome","phase":"NA","overall_status":"UNKNOWN","enrollment_count":512,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT01461278","title":"Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":505,"lead_sponsor_name":"Glaukos Corporation","has_results":false},{"nct_id":"NCT05405868","title":"Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":496,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT04024072","title":"To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":495,"lead_sponsor_name":"Padagis LLC","has_results":true},{"nct_id":"NCT02339584","title":"Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":493,"lead_sponsor_name":"Alcon Research","has_results":true},{"nct_id":"NCT04944290","title":"To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":447,"lead_sponsor_name":"Padagis LLC","has_results":true},{"nct_id":"NCT03284853","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":436,"lead_sponsor_name":"Aerie Pharmaceuticals","has_results":true},{"nct_id":"NCT06441643","title":"Next Generation Rocklatan","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":426,"lead_sponsor_name":"Alcon Research","has_results":false},{"nct_id":"NCT01749904","title":"Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":420,"lead_sponsor_name":"Bausch & Lomb Incorporated","has_results":true},{"nct_id":"NCT05181046","title":"Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":420,"lead_sponsor_name":"Nanodropper, Inc.","has_results":false},{"nct_id":"NCT03235232","title":"BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":406,"lead_sponsor_name":"EMS","has_results":false},{"nct_id":"NCT05159960","title":"Optimal Treatment Protocol for Selective Laser Trabeculoplasty - Repeat Trial","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT03798223","title":"Optimal Treatment Protocol for Selective Laser Trabeculoplasty","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT04133311","title":"A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":386,"lead_sponsor_name":"Santen SAS","has_results":true},{"nct_id":"NCT03762369","title":"A Clinical Study to Evaluate the Efficacy and Safety of CKD-351","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":384,"lead_sponsor_name":"Chong Kun Dang Pharmaceutical","has_results":false},{"nct_id":"NCT04475900","title":"Computer-aided Diagnosis of Ocular Diseases Based on Corneal Biomechanics","phase":"","overall_status":"COMPLETED","enrollment_count":372,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT02617459","title":"Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":366,"lead_sponsor_name":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","has_results":false},{"nct_id":"NCT01735214","title":"An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments","phase":"","overall_status":"COMPLETED","enrollment_count":358,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT06993311","title":"Real World Evidence of Xen45 Gel Implant in Pseudoexfoliation Glaucoma","phase":"","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Xerencia de Xestión Integrada de Ferrol","has_results":false},{"nct_id":"NCT06666855","title":"A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":345,"lead_sponsor_name":"Santen Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05495061","title":"A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":325,"lead_sponsor_name":"Santen Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04742283","title":"Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":323,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT00572455","title":"Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04899063","title":"Excimer Laser Trabeculostomy Glaucoma Treatment Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"Elios Vision, Inc.","has_results":false},{"nct_id":"NCT04890106","title":"Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":310,"lead_sponsor_name":"Mankind Pharma Limited","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}